1
/
of
0
FDA FAERS Report – IZERVAY (Nov 7–15, 2024)
FDA FAERS Report – IZERVAY (Nov 7–15, 2024)
Regular price
$69.00 USD
Regular price
Sale price
$69.00 USD
Unit price
/
per
Original Request: I would like to request full reports of any and all adverse events reported to the FAERS database for IZERVAY (branded name / marketed by Astellas Pharma Inc.) or avacincaptad pegol intravitreal solution (generic name) between November 7, 2024, and November 15, 2024. Please provide the documents electronically if possible.
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details